Following the publication of its first clinical study earlier this year, the company is expanding its research program through new human investigations designed to further characterise the performance of bonded phospholipid omega-3 delivery across multiple health applications.
Key study parameters
- 24 weeks Intervention duration
- 100+ participants Expected enrolment
- Double-blind RCT Randomised, controlled design
This registration marks another milestone in the scientific development of the Ruby-O platform and reflects Naturmega’s broader commitment to advancing next-generation omega-3 delivery systems.
One of these studies is now officially registered on ClinicalTrials.gov. The randomised, double-blind trial will evaluate Ruby-O phospholipid omega-3 versus conventional formulations in adults with mixed dyslipidemia, examining omega-3 incorporation, metabolic markers, and cardiovascular outcomes over a 24-week intervention. Enrollment is expected to exceed 100 participants.
2026 scientific roadmap
Beyond this trial, additional clinical investigations are already planned as part of the 2026 Ruby-O scientific roadmap, reinforcing the company’s long-term investment in differentiated lipid technologies and evidence based innovation.
For further details on Ruby-O®, please visit naturmega.com
